People

Fellow Mentors
  • Mr. Abel Ang

    Group Chief Executive Officer, Accuron MedTech

    Mr Abel Ang is the Group Chief Executive Officer of Accuron MedTech, where he has overall responsibility for Accuron’s Medical Device activities.

    Abel has a proven track record in the medical device sector. He has served as the Senior Advisor to the CEO of Greatbatch Inc (NYSE:GB), providing guidance relative to the commercialization of medical device technologies in the cardiac, neurology, vascular and orthopaedic markets. Prior to Greatbatch, Abel was President, Asia/Pacific for Hill-Rom Inc. a US$1.7B revenue medical devices company (NYSE: HRC) where he was responsible for leading, developing and implementing the strategy to expand Hill-Rom’s presence in the Asia/Pacific markets. He formerly served as the Chief Technology Officer for Hill-Rom for 3 years. In that role he had overall responsibility for Hill-Rom’s global R&D operations which are distributed across sites in the U.S., Mexico, France, and Singapore. At Hill-Rom, he also held the positions of Vice- President and General Manager of Hill-Rom’s US$420MM Global Surfaces and Therapy Business Unit; and Vice-President for International Business and Technology Development. He formerly headed the global Medical Technology and Biotechnology industry groups in the Singapore Economic Development Board’s (EDB) Biomedical Division.

    Ang sits on the Board of Economic Development Innovations Singapore, a privately-held company headquartered in Singapore with offices in Germany and the US. With expertise honed in conceiving and managing townships in India, Vietnam, China and Indonesia, EDIS’ core business is in investing, managing and developing integrated cities globally. Ang also sits on the Board of Exploit Technologies which provides access to Singapore's largest pool of intellectual property and knowledge generated by over 2,000 researchers at A*STAR's research institutes. In addition, he sits on the Boards of the following Accuron Medical Device Operating companies: Dornier Medizintechnik, Veredus Pte Ltd, and Advanced Materials Technologies (AMT) Pte Ltd.

    Abel is an Adjunct Associate Professor at the Nanyang Business School in Singapore and Waseda University in Japan, where he teaches in their respective MBA programs.

    Mr Ang has a Master of Science in Computational Biology from Rutgers University in New Jersey, which he pursued while on an EDB scholarship. He attended Harvard Business School’s Advanced Management Program in 2012.

  • Mr. Alok Mishra

    Vice President, Strategic Business Systems, Johnson & Johnson Medical Asia Pacific

    Mr Alok Mishra is currently the Vice President, Strategic Business Systems, Johnson & Johnson Medical Asia Pacific. Alok has worked in Johnson & Johnson for over 17 years and has held positions as Franchise Manager Cordis, Managing Director of Singapore and India and as the Area Vice President, South Asia Region.

    Alok has a Master’s Degree in Pharmacy and MBA from IIM Ahmedabad. He began his career in marketing in multinational companies in India viz, Boots Pharmaceuticals & Burroughs Wellcome and with a distribution company in the Middle East.

    He is a Member of MENSA.

    He is an adjunct faculty member at the MBA Program of National University of Singapore and Singapore Management University.

    Alok has wide exposure to the health care industry – Pharmaceuticals, Consumer Pharmaceuticals and Medical Devices and was a Council member of the Singapore Manufacturing Association and Chairman of the India Business Group covering India, Middle East, Central Asia and Africa. He was also the Chairman of Medical Technology & Life Sciences Industry Group of Singapore Manufacturing Federation. In the past he has held positions of Chairman of Medical Technology Standards Committee of the Standards Council and Chairman of Medical Technology Group, Confederation of Indian Industry (CII).

  • Ms. Dorothea Koh

    Founder & CEO, Bot M.D.

    Dorothea Koh is the General Manager for Indonesia & Philippines at Baxter Healthcare where she is responsible for driving accelerated access and growth for Baxter’s Renal and Hospital Products businesses to impact more patients living in these two emerging markets.

     

    Prior to this role, Dorothea was the Director of Business Model Innovation at Baxter China where she was responsible for leading a multidisciplinary team to create and commercialize disruptive new business models for Baxter’s Renal and Fluid Systems portfolios.  

     

    Dorothea joined Baxter in 2012 as Senior Program Leader, International.  She began her career as a Senior Officer in the Singapore Economic Development Board before joining Medtronic as a Senior Manager, Business Development & Strategy.

     

    Dorothea graduated summa cum laude with a B.S. in Biomedical Engineering and Economics from Northwestern University, and received her M.S. in Bioengineering from Stanford University.  She is the youngest fellow to be awarded the Stanford Biodesign Innovation Fellowship where she helped to innovate new medical technologies for the critical care and electrophysiology fields.

     

    Dorothea is the lead inventor on six published and pending patents. In her spare time, she enjoys listening to classical and jazz music as well as running, swimming and golf.    

  • Dr. Eitan Konstantino

    CEO, Co-Founder, QT Vascular Ltd

    QT Vascular Ltd (SGX:5i0) is the parent company of TriReme Medical, LLC, TriReme Medical (Singapore) Pte Ltd and Quattro Vascular Pte Ltd. The Group is engaged in the design, assembly and distribution of advanced therapeutic solutions for the minimally invasive treatment of complex vascular diseases. QT Vascular Ltd is a public listed company on the SGX Catalist board.

    Prior to leading QT Vascular Ltd., Dr. Konstantino founded TriReme Medical, LLC and Quattro Vascular Pte Ltd., Dr. Konstantino was co-founder, President and Chief Scientist of AngioScore, Inc. from its inception until 2007. Dr. Konstantino is the primary inventor of the AngioSculpt catheter and the Easy Exchange delivery system. Previously, Dr. Konstantino was the CEO & COO of Advanced Stent Technologies (“AST”), a bifurcation stent company that was acquired by Boston Scientific in 2004. He co-invented the Petal bifurcation stent that is currently with Boston Scientific. Prior to AST, he was Chief Technical Officer of Bypass Ltd, a developer of nitinol anastomotic devices for minimally invasive heart surgery. Dr. Konstantino is co-founder of Singapore Medtech Accelerator (“SMA”), an appointed Biomedical Science Accelerator (“BSA”) under the Singapore Government’s Research, Innovation and Enterprise 2015 plan. Dr. Konstantino is also an appointed member of Singapore’s government SPRING Medtech Network of Advisors.

    Dr. Konstantino received his PhD from Technion - Israel Institute of Technology.

  • Dr. Gary Binyamin

    Director of Technology, Quattro Vascular Pte Ltd

    Not Available.

  • Mr. Jack Wang

    Ex-CEO, Biosensors International

    Not Available.

  • Mr. Jose (Pepe) Calle Gordo

    Vice Chairman of the Board, Biosensors International Group Ltd

  • Mr. Lu Yoh-Chie

    Executive Chairman, Biosensors International Ltd

    Mr. Lu, the founder of Biosensors International Group Ltd, was its chairman and CEO from its inception to 2008. He retained his leadership position as chairman of the Group since January 2008.


    Mr. Lu has more than 30 years’ experience in the medical industry. As chairman, Mr. Lu’s experience, leadership and track record has proven to be critical. While serving as CEO, he was responsible for Biosensors’ business strategies and directions, the implementation of corporate plans and policies, and the general management of business.


    Prior to founding the Company, Mr. Lu established Asia-based operations for the Medical Division of Gould Inc., which specialized in surgical and critical care catheters and instruments. He held various senior positions with Gould before advancing to the position of president of the Asia-Pacific division. In 1986, Mr. Lu participated in a management-led leveraged buyout of the division from Gould. He continued as president of the Asia-Pacific division through 1988 until it was sold to British Oxygen Corporation. He then served as president of Asia-Pacific with British Oxygen until 1990. In 1990, Mr. Lu also founded Sun Instruments-Japan, Sunscope International in California and Biosensors International in Singapore, all of which are now subsidiaries of Biosensors International Group, Ltd.


    Mr. Lu holds a Bachelor of Science degree in Engineering from the University of California at Berkeley and a Masters degree in Business Administration from the Thunderbird Graduate School of International Management in Arizona.

  • Dr. Lye Whye Kei

    Director, Business Development (Future Healthcare), NTUitive Pte Ltd

    CEO, SysteMED Pte Ltd

  • Mr. Scott Wolf

    Founder and CEO, Aerin Medical

    Dr. Scott Wolf is a prolific medical device entrepreneur. Over the past 20 years, Scott founded numerous successful medical device companies across a broad range of therapeutic areas.

    Scott is the founder and President of Aerin Medical, a company developing a non-surgical therapy to meet the enormous need of patients with nasal obstruction and rhinitis.

    Prior to founding Aerin Medical, Scott founded Zeltiq Aesthetics, the maker of CoolSculpting, the leading non-invasive method of fat reduction for bodysculpting. Scott’s other startups include Endogastric Solutions and Cardiac Dimensions. Scott was previously a partner at Prospect Venture Partners and a vice-president at Frazier Healthcare Ventures, both leading life science venture capital firms.

    Scott received his M.D. from George Washington University and his B.A. from the University of Pennsylvania.

  • Dr. Steven Fang

    CEO, Capbridge Accelerator

    Partner, Clearbridge Accelerator

    Lorem ipsum dolor sit amet, prima minim cum et, sit ceteros reprimique te. Mei modo malorum no. Qui eros aliquam sententiae in, natum interpretaris mea et. Nonumy euismod et mei, duo vidisse nostrud euripidis no. Sit no percipitur scribentur. Vel in quod vitae equidem. Quot oblique id quo, no mei putent consequuntur. Invenire scriptorem in mei. Vel ignota nominavi lucilius et, ei usu consul accusamus salutatus, et falli decore cum. Et fabellas principes cum. Eam in oportere dissentias. Amet mazim intellegam ad per, te vocent vocibus percipit pri, ius ne quod tacimates sensibus.
Class Speakers
  • Mr. Abel Ang

    Group Chief Executive Officer, Accuron MedTech

    Mr Abel Ang is the Group Chief Executive Officer of Accuron MedTech, where he has overall responsibility for Accuron’s Medical Device activities.


    Abel has a proven track record in the medical device sector. He has served as the Senior Advisor to the CEO of Greatbatch Inc (NYSE:GB), providing guidance relative to the commercialization of medical device technologies in the cardiac, neurology, vascular and orthopaedic markets. Prior to Greatbatch, Abel was President, Asia/Pacific for Hill-Rom Inc. a US$1.7B revenue medical devices company (NYSE: HRC) where he was responsible for leading, developing and implementing the strategy to expand Hill-Rom’s presence in the Asia/Pacific markets. He formerly served as the Chief Technology Officer for Hill-Rom for 3 years. In that role he had overall responsibility for Hill-Rom’s global R&D operations which are distributed across sites in the U.S., Mexico, France, and Singapore. At Hill-Rom, he also held the positions of Vice-President and General Manager of Hill-Rom’s US$420MM Global Surfaces and Therapy Business Unit; and Vice-President for International Business and Technology Development. He formerly headed the global Medical Technology and Biotechnology industry groups in the Singapore Economic Development Board’s (EDB) Biomedical Division.


    Ang sits on the Board of Economic Development Innovations Singapore, a privately-held company headquartered in Singapore with offices in Germany and the US. With expertise honed in conceiving and managing townships in India, Vietnam, China and Indonesia, EDIS’ core business is in investing, managing and developing integrated cities globally. Ang also sits on the Board of Exploit Technologies which provides access to Singapore's largest pool of intellectual property and knowledge generated by over 2,000 researchers at A*STAR's research institutes. In addition, he sits on the Boards of the following Accuron Medical Device Operating companies: Dornier Medizintechnik, Veredus Pte Ltd, and Advanced Materials Technologies (AMT) Pte Ltd.


    Abel is an Adjunct Associate Professor at the Nanyang Business School in Singapore and Waseda University in Japan, where he teaches in their respective MBA programs.


    Mr Ang has a Master of Science in Computational Biology from Rutgers University in New Jersey, which he pursued while on an EDB scholarship. He attended Harvard Business School’s Advanced Management Program in 2012.

  • Mr. Alfred Kwek

    Director, Regulatory Affairs, ASEAN, GE Healthcare

    Not Available.

  • Mr. Alok Mishra

    Vice President, Strategic Business Systems, Johnson & Johnson Medical Asia Pacific

    Mr Alok Mishra is currently the Vice President, Strategic Business Systems, Johnson & Johnson Medical Asia Pacific. Alok has worked in Johnson & Johnson for over 17 years and has held positions as Franchise Manager Cordis, Managing Director of Singapore and India and as the Area Vice President, South Asia Region.


    Alok has a Master’s Degree in Pharmacy and MBA from IIM Ahmedabad. He began his career in marketing in multinational companies in India viz, Boots Pharmaceuticals & Burroughs Wellcome and with a distribution company in the Middle East.


    He is a Member of MENSA.


    He is an adjunct faculty member at the MBA Program of National University of Singapore and Singapore Management University.


    Alok has wide exposure to the health care industry – Pharmaceuticals, Consumer Pharmaceuticals and Medical Devices and was a Council member of the Singapore Manufacturing Association and Chairman of the India Business Group covering India, Middle East, Central Asia and Africa. He was also the Chairman of Medical Technology & Life Sciences Industry Group of Singapore Manufacturing Federation. In the past he has held positions of Chairman of Medical Technology Standards Committee of the Standards Council and Chairman of Medical Technology Group, Confederation of Indian Industry (CII).

  • Mr Amit Anand

    Board Director, Business Angel Network South-east Asia (BANSEA)

    Not Available.

  • Dr. Casey Chan

    Partner, Venture MD

    Not Available.

  • Mr. Colin Tan

    Chief Operating Officer, Endomaster Pte Ltd

  • Ms. Dorcas Tan

    founder and CEO, Recruit Inc Pte Ltd

  • Dr. Dianne Bautista

    Senior Biostatistician, SCRI
  • Mr. Damien Lim

    General Partner, BioVeda Capital

    Not Available.

  • Ms. Dorothea Koh

    Founder & CEO, Bot M.D.

  • Dr. Eddy Lee

    Managing Partner, Coffee Ventures

  • Dr. Foo Fatt Kah

    Managing Director and Founder, Luminor Capital

    Dr Foo is Managing Director and co-founder of Luminor Capital Pte Ltd, a Singapore-based private equity fund management company. Healthcare is a key focus of Luminor Capital’s investment strategy. Dr Foo has over 20 years of experience in investment banking, venture capital, private equity investments, financial advisory and consulting. He started his career as an equity analyst specialising in the pharmaceutical and biotechnology sector in Europe, working at Robert Fleming & Co, Barings Securities and Paribas Capital Markets in London, UK. He was a rated analyst in the Institutional Investor and Extel European polls. He returned to Asia in 1994 and has lived and worked both in Hong Kong and Singapore with Deutsche Morgan Grenfell (now Deutsche Bank) and Societe General (SG). He was latterly Head of Asian Equities and Co-Head of the Investment Bank for SG Securities Asia covering 10 Asian countries. He was the Asian Venture Partner for Aravis Ventures, a global venture capital firm specializing in Biotechnology and Energy investments between 2004~2012 and was a founding member of BioSingapore, the industry association for the biosciences industry and served as its Honorary Treasurer following its inception for a statutory period of 2 years. Dr. Foo is qualified in Medicine (M.B., B. Ch., B.A.O.) and Business Administration (MBA) from Queen's University, UK.

  • Mr. Jack Wang

    Ex-CEO, Biosensors International

    Not Available.

  • Mr. Johnson Chen

    Managing Partner, Clearbridge Accelerator

    Not Available.

  • Dr. Laurent Metz

    MD, Director, Health Economics and Market Access, Johnson & Johnson Medical Asia-Pacific

    Dr Laurent Metz is the Senior Director of Health Economics, Market Access and Clinical Research for Johnson & Johnson Medical Asia- Pacific. He has been working in Health Economics, Outcome Research and Reimbursement with Johnson & Johnson for the past 17 years in Asia Pacific, Europe and in the United States. He has led the development and implementation of health economics and evidence generation strategies in most of the markets around the world and has been involved in multiple submissions to Health Technologies Assessment Bodies. With the Eucomed in Europe, he has contributed to the development of position papers on the specificities of medical devices evaluation. He was the Chairman of the Eucomed Funding and Reimbursement task force. 

    Dr Laurent Metz is a Medical Doctor graduated from the University of Medicine of Nancy, France. He has a MBA from HEC Business School, Paris, France. He completed the Advanced Strategic Management program at IMD, Lausanne (Switzerland), executive course in Health Economics at the Stockholm School of Economics and Value Measurement for Health Care program by Harvard Business School. 

    Dr Laurent Metz is member of the International Society of Health Economics & Outcome Research, of the Society for Medical Decision Making.

  • Dr. Lawrence Ho

    Chief Medical Officer and Co-founder, Endomasters Pte Ltd

  • Mr. Leif R. Sloan

    Patent Director, Axis Intellectual Capital

    Not Available.

  • Mr. Lu Yoh Chie

    Executive Chairman, Biosensors International Ltd

    Mr. Lu, the founder of Biosensors International Group Ltd, was its chairman and CEO from its inception to 2008. He retained his leadership position as chairman of the Group since January 2008.

    Mr. Lu has more than 30 years’ experience in the medical industry. As chairman, Mr. Lu’s experience, leadership and track record has proven to be critical. While serving as CEO, he was responsible for Biosensors’ business strategies and directions, the implementation of corporate plans and policies, and the general management of business.

    Prior to founding the Company, Mr. Lu established Asia-based operations for the Medical Division of Gould Inc., which specialized in surgical and critical care catheters and instruments. He held various senior positions with Gould before advancing to the position of president of the Asia-Pacific division. In 1986, Mr. Lu participated in a management-led leveraged buyout of the division from Gould. He continued as president of the Asia-Pacific division through 1988 until it was sold to British Oxygen Corporation. He then served as president of Asia-Pacific with British Oxygen until 1990. In 1990, Mr. Lu also founded Sun Instruments-Japan, Sunscope International in California and Biosensors International in Singapore, all of which are now subsidiaries of Biosensors International Group, Ltd.

    Mr. Lu holds a Bachelor of Science degree in Engineering from the University of California at Berkeley and a Masters degree in Business Administration from the Thunderbird Graduate School of International Management in Arizona.

  • Dr. Lye Whye Kei

    Director of Business Development (Future Healthcare), NTU

    Not Available.

  • Ms. Nynke Kinderman

    New business development & Innovation Consultant

    Not Available.

  • Mr. Shen Nansheng

    SPRING Singapore

    Not Available.

  • Dr. Stanley Lai

    Head of the Intellectual Property, Allen & Gledhill LLP

    Not Available.

  • Mr. Steven Fang

    CEO, Capbridge Accelerator

    Partner, Clearbridge Accelerator

    Not Available.

  • Mr. Supratim Bose

    Executive Vice President and the President of Asia-Pacific, Boston Scientific

    Supratim Bose is Executive Vice President and President, Asia-Pacific, Middle East & Africa for Boston Scientific, and a member of its Executive Committee. In this role, Supratim oversees the Company’s business and growth opportunities across Asia-Pacific, Middle East & Africa, the world’s fastest growing region.

    Before joining Boston Scientific in January 2012, Supratim was Founder and Chief Executive Officer of Singapore-based Bose Consulting Group, which specialized in strategic management consulting services for the healthcare industry. Prior to that, he was with Johnson & Johnson (J&J) for nearly 30 years, where he concluded his tenure as Company Group Chairman of its Medical Devices and Diagnostics (MD&D) business. In that role, he managed J&J’s MD&D companies throughout Asia-Pacific, including Japan, having pioneered its entry in all emerging markets in Asia, including China, India, and Vietnam. During his tenure, he also created the company’s research and development capability in the region and led the development and growth of local talent. Under Supratim’s leadership, the organization partnered closely with key external stakeholders to shape the healthcare environment, and was recognized by external agencies as one of the top companies to work for in Asia-Pacific.

    Supratim joined J&J Ltd. India in 1981, and held a variety of management positions of increasing responsibility leading up to his appointment as Company Group Chairman of MD&D. He has extensive and proven experience in building markets in this region. Prior to J&J, he served at one of the top growing pharmaceutical start-ups in India.

    Supratim earned a B.Sc. in Chemistry/Physics, a M.Sc. in Biophysics and a Master in Management Studies (MMS) from the Jamnalal Bajaj Institute of Management Studies at the University of Bombay. He served as a member of the Board of Directors at CareFusion Corporation, Quattro Vascular Pte Ltd and Trireme Medical, and member of the Advisory Board at Singapore Management University’s Lee Kong Chian School of Business.

  • Mr. Sundeep Shrivastava

    Director Clinical Operations, Medical Device, APAC, Quintiles

  • Prof. Suzanne Leong

    Professor, National University Singapore Business School

    Not Available.

  • Prof Tan Sze Wee

    Executive Director, Science and Engineering Council (SERC), A*STAR

    Prof Tan Sze Wee, is currently the Executive Director of A*STAR’s Science and Engineering Council (SERC).


    Prof Tan’s career in A*STAR began in 2009, where he held the appointment of Programme Director of the Medical Technology initiative in SERC. His next appointment was as Director of SERC’s Strategic Initiatives, where he oversaw all SERC cluster-led R&D development. He also provided leadership for SERC’s cross-cutting programmes such as the Thematic Research Programme and the Joint Laboratories programme with the local universities and concurrently spearheaded the Healthcare and Lifestyle (H&L) Programme in A*STAR.


    In October 2012, Prof Tan was promoted to Deputy Executive Director in the Biomedical Research Council (BMRC). His experience with the SERC RIs enabled BMRC to engage companies in these industry sectors holistically, cross-promoting the multi-disciplinary capabilities available at both Councils to meet the needs of companies. He helped to pave the way for growth of A*STAR’s engagements with companies in the Food & Nutrition, Medical Technology and Consumer Care sectors with leading MNCs like GE Healthcare, Nestle, Coca Cola and P&G.


    Prof Tan is Adjunct Professor at Nanyang Technological University’s School of Chemical and Biomedical Engineering and Lee Kong Chian School of Medicine, as well as an Adjunct Associate Professor at Duke-NUS Graduate Medical School Singapore. He is also Chairman of the Singapore Stanford Biodesign Steering Committee, and member of the steering committee of Rehabilitation Research Institute of Singapore.


    Prof Tan was formerly the Managing Director and Chief Executive Officer of Rockeby Biomed Limited. Prior to joining Rockeby, he was the Asia-Pacific Associate Regional Medical Director (Asia Regional Office) for Mead Johnson Nutritionals, a division of Bristol-Myers Squibb Company from 1997 to 2001.


    Prof Tan was a former Nominated Member of Parliament of Singapore.

  • Ms. Tan Hwee Ee

    Director/ Principal Consultant, DH RegSys
  • Mr. Tay Lai Hock

    Vice President, Medtronic

    Not Available.

  • Mr. Teng Leng

    Senior Regulatory Specialist, Medical Device Group, HSA 

    Not Available.

  • Dr. Teoh Yee Leong

    Chief Executive Officer, Singapore Clinical Research Institute (SCRI)

    Not Available.

  • Dr. Ting Choon Meng

    Executive Chairman & CEO, HealthSTATS International

    Dr.Ting is a medical doctor, serial inventor of medical devices and an author. He is in private practice in Singapore for more than 20 years. BPro device is the first wrist-worn device capable of capturing 24hr BP readings and Pulse waveform analysis both at the same time. This patented invention which is FDA approved has won Awards from World Economic Forum and Frost & Sullivan as Monitoring Technology of the year 2007. BPro is now commercialized in more than 25 countries in the world.

    Dr.Ting’s other inventions includes a non-invasive blood glucose monitor, a smart needle for intra-articular injection and a mobile ER vehicle for mass casualty that is now the standard deployment in the Singapore Homeland Defense Force. 

    Dr. Ting has also pioneered the technique of Visco-supplementation for the treatment of OA knees since 1991. He has done more than 25,000 knees to date and has written a handbook for doctors. It was launched in Beijing in August 2007.

    . Dr. Ting is still actively involved in clinical practice, spending half of his time in the clinic and the other half in research. 

    Dr. Ting has also been appointed as a member of the Enterprise Board for the Institute of Innovation and Entrepreneurship (IIE) recently formed under the Singapore Management University (SMU). He is also on the Advisory Board of the Wee Kim Wee Center in SMU.

    In April 2008, he founded the Singapore Fellowship of Inventors (S-FOI), a non-profit organization dedicated to the education, support and networking of fellow entrepreneurs and inventors. The monthly meetings will culminate in an annual convention of INVENT SINGAPORE held since 2008. 

    In March 2009, Dr. Ting has also been appointed as a member of the evaluation panel of the National Research Foundation of Singapore and evaluated the submission of projects for funding in bio-medical cluster. Furthermore, he also served on the Economic review Committee of the Singapore Government in 2009. 

    In year 2010, Dr. Ting has been invited to become an International Faculty Member of the Leicester National Institute for Health Research (NIHR) Cardiovascular Biomedical Research Unit (BRU) based in the U.K. He is the first and honored member to be invited whom is based outside of U.K region. Later on, he was appointed as an Innovation Grant Advisory Board Member for Singapore-MIT Alliance for Research and Technology (SMART) and successfully evaluated the biomedical/life sciences proposals. 

    Dr. Ting has been an Adjunct Professor of the School of Mechanical & Aerospace Engineering, Nanyang Technological University from June 2012 to May 2015.

    Recently, in January 2015, Dr. Ting has been appointed as an Adjunct Professor by the China Air Force, Beijing Hospital.

  • Mr. Ulrich Schraudolph

    Design Director, Xentiq Pte Ltd

    Ulrich Schraudolph is Founding Company Director and R & D Director at XentiQ Pte Ltd, a product development consultancy specialized in early stage Biomed and Industrial productization, based in Singapore. 

    Ulrich has more than 25 years of product design experience, working many years in product design consultancies in France and Singapore, after studies in Germany, Switzerland and the United States, where he attended Art Center College of Design. He also holds a Masters in Human Factors Engineering (Ergonomics) from Nanyang Technical University (NTU). 

    Client track record includes multinational corporations such as Colgate, Unilever in fast moving consumer products, well-known consumer brands in the sports sector like Atomic, Look, Oxygen and Schuberth; Alcatel, Alstom, Sagem, Hyflux, Singapore Technologies in the technology sector; as well as SME's in fields ranging from electronics and industrial equipment to furniture, optical and medical products among others. A special focus have been high-tech startups such as Spineguard, Curiox, Histoindex, Ecosoft and Sentec

    Ulrich has been a consultant with the Korean Institute of Design and Packaging (KIDP) and a lecturer at CREAPOLE design school in Paris, at National University of Singapore (NUS), Nanyang Technological University (NTU) and Singapore Stanford Biodesign (SSB), among other lecturing activities.

  • Mr. Victor Tsui

    Vice President, General Manager Asia Pacific of Edwards Lifesciences (Asia) Pte ltd

    Not Available.

  • Mr. Vincent Cheung

    Principal Consultant, Applied Quality Systems Pte Ltd

    Not. Available.

  • A/Prof. Wan Chew Yoong

    Nanyang Technological University

    Not Available.

  • Dr. Wong Chiang Yin

    MBBS, Group Chief Executive Officer & Executive Director, TMC Life Sciences Bhd

    Not Available.

  • Ms. Yvette Flanigan

    Technical Expert, Viering, Jentschura & Partners

    Yvette received her first degree from the University of Queensland. She has a first class honours degree and Ph.D. in Biochemistry also from the University of Queensland. She later obtained her Grad. Cert. in I.P. Law from the National University of Singapore. She was awarded a certificate in patent drafting by the Southeast Asian Drafting Patents Board of FICPI.

    Yvette is a Senior Patent Scientist at the boutique IP firm Yusarn Audrey and is involved in Intellectual property registration and prosecution work.

    Recently, she took time out to work as a Technical Expert at a European Patent Attorney firm in Singapore. Prior to joining Yusarn Audrey Yvette was a Senior manager of the Intellectual Property division of Exploit Technologies Pte. Ltd. of the Agency for Science, Technology and Research.

    Yvette was previously a Biotechnology consultant with one of the leading law firms in Singapore. 

    Yvette has been heavily involved in Singapore’s fledgling Biotechnology industry and was on the founding executive council members of the BioSingapore trade organization in 2004 and 2005 the Honorary Secretary in 2007, and the Honorary Treasurer in 2014.

    Prior to branching into IP law she has worked as a research scientist at Dupont Singapore; at the National University of Singapore (NUS); Nanyang Technological University (NTU); and at the University of Queensland, Australia as well as a short project at Research School of Biological Sciences, Australia National University.